Undisclosed ADAR1 inhibitor / Accent Therap - LARVOL DELTA

Accent Therapeutics Unveils XRN1 Program and Provides Pipeline Update with Presentations at 35th AACR-NCI-EORTC Symposium (PRNewswire) - "ADAR1 has emerged as a promising, yet challenging-to-drug, oncology target for which inhibition has been shown to induce downstream immune activation and subsequent cell death in cancer cells with high intrinsic type 1 interferon signaling-a trait that 15-30% of primary tumors share....The company's final presentation at the meeting...will demonstrate that DHX9 inhibition in microsatellite instable tumors exhibiting defective mismatch repair induces replication stress and subsequent cell death."

Preclinical • Solid Tumor